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Ventricular fibrillation is the leading cause of sudden cardiac death.
In fibrillation, fragmented electrical waves meander erratically
through the heart muscle, creating disordered and ineffective
contraction. Theoretical and computer studies, as well as recent
experimental evidence, have suggested that fibrillation is created
and sustained by the property of restitution of the cardiac action
potential duration (that is, its dependence on the previous diastolic
interval). The restitution hypothesis states that steeply sloped
restitution curves create unstable wave propagation that results in
wave break, the event that is necessary for fibrillation. Here we
present experimental evidence supporting this idea. In particular,
we identify the action of the drug bretylium as a prototype for the
future development of effective restitution-based antifibrillatory
agents. We show that bretylium acts in accord with the restitution
hypothesis: by flattening restitution curves, it prevents wave break
and thus prevents fibrillation. It even converts existing fibrillation,
either to a periodic state (ventricular tachycardia, which is much
more easily controlled) or to quiescent healthy tissue.
In ventricular fibrillation (VF), the leading cause of suddencardiac death, multiple vortex-like (‘‘re-entrant’’) waves of
electrical excitation meander erratically through the ventricular
muscle (1–3). But VF usually begins with a more orderly stage
(Wiggers’ stage I), consisting of just one or a pair of spiral waves,
which then break down into the multispiral disordered state that
is VF (4). Because the individual waves in VF have short
lifetimes (less than half a second; ref. 5), both the breakdown into
VF and the continued maintenance of VF require a continual
formation of new waves, through the process of wave break, in
which a single wave splits in two. There are two schools of
thought about the cause of wave break. Experimentalists tradi-
tionally have emphasized the importance of pre-existing elec-
trophysiological and anatomical heterogeneity (such as a ‘‘dis-
persion of refractoriness;’’ refs. 6 and 7). But recently, Karma
and other theorists have suggested that dynamic heterogeneity,
arising from cardiac restitution properties, may be more critical
(8–11). Restitution refers to the fact that the cardiac action
potential duration (APD) and its conduction velocity (CV) both
depend on the previous diastolic interval (DI), which is the rest
period between repolarization and the next excitation. The
restitution hypothesis of VF states that the slope of the APD
restitution (APDR) curve, in which APD is plotted against the
preceding DI, is the main determinant of wave break (10). When
the slope of this curve is steep (.1) over a sufficient range of DIs,
small differences in DI, as might be experienced at different
points on a wave front, will be amplified into larger differences
in APD. These create larger differences in the following DI, etc.
If this oscillation in APD grows large enough, action potential
failure occurs, causing wave break (8–12). In contrast, if the
APDR slope is ,1, perturbations in APD and DI are damped
rather than amplified, which resists wave break. A critical
prediction of the restitution hypothesis is that a drug that reduces
the slope of the APDR curve to ,1 everywhere should have
potent antifibrillatory effects, by preventing wave break.
Recently, two drugs that lower the slope of the APDR curve
have been shown to prevent fibrillation in canine ventricle (13).
The calcium channel blocker verapamil and the electro-
mechanical uncoupler diacetyl monoxime each lowered the
slope of the APDR curve, and both prevented the induction of
VF and converted existing VF to a periodic rhythm. However,
that study did not map the tissue spatially and so was unable to
confirm that the mechanism was the prevention of wave break.
Here, we extend these experimental results by showing that
bretylium, a drug whose pharmacology is completely distinct
from that of either verapamil or diacetyl monoxime, also flattens
restitution, and both prevents the induction of VF and converts
VF into a periodic rhythm (or quiescent tissue). In addition, by
using voltage-sensitive dyes to map the electrical activity in the
tissue, we show that the mechanism of action of bretylium against
VF is indeed suppression of spiral wave breakup, thus confirming
the restitution hypothesis mechanistically.
Methods
Surgical Preparation. As described in detail (14), the right coro-
nary arteries of farm pigs were cannulated and perfused with
oxygenated Tyrode’s solution at 36°C, and the well-perfused
right ventricular free wall was surgically isolated. The tissue was
placed with the endocardial side down in a tissue bath containing
a built-in electrode array with 478 bipolar recording electrodes
(1.6-mm interelectrode distance). Transmembrane potential was
recorded from the epicardial surface (15).
Study Protocol. All pacing was performed with twice diastolic
threshold current. To determine APDR curves, two methods
were used. For the S1-S2 method, the tissue was paced at a 400-ms
cycle length (S1) for eight beats, followed by a single premature
stimulus (S2). The S1-S2 coupling interval was progressively
reduced until the S2 failed to capture. For the dynamic pacing
method, (used to sample very short DIs) eight paced beats were
delivered at progressively shorter cycle lengths (400, 350, 300,
280, 260, 240, 230, 220, 210, 200, 190, 180, 170, 160, and 150 ms).
After baseline measurements, bretylium (1 mgyml) or bretylium
1 cromakalim (2.86 mgyml) was added to the perfusate, and the
measurements were repeated after 15 min. The concentration of
bretylium was progressively increased (5, 10, 20, and 40 mgyml)
until VF terminated or converted to a periodic ventricular
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tachycardia (VT). Afterward, rapid pacing was used to test
whether or not VF was inducible. Each pacing train included 19
beats, and there was an interval of at least 20 sec between pacing
trains. The pacing interval started at 250 ms and was progres-
sively shortened in 10-ms decrements until VF was induced or 1:1
capture failed and 2:1 capture resulted. We then attempted to
induce VF with ultrashort (50 ms) intervals and repeated this at
least three times for each tissue. When VF was not induced, the
APDR curve was redetermined.
Data Analysis. APD was measured at 90% repolarization
(APD90), and the DI was defined as the difference between the
interactivation interval and APD90. APDR slopes were calcu-
lated by single exponential fits to the data. (All fits were
statistically significant by x2 criteria.) All data are presented as
mean 6 SD. Student’s t test or Newman-Keuls ANOVA were
used for statistical comparisons (16), with a P value # 0.05
considered significant.
Optical Mapping. The optical mapping system used in the present
study has been described in detail (17). The tissues were
stained for 20 min with 1–2 mM pyrimidine 4-(2-(6-
(dibutylamino)-2-naphthalenyl)-1-(3-sulfopropyl) hydroxide
(di-4-ANEPPS, Molecular Probes) added to the Tyrode’s
solution. The dye then was excited by using quasimonochro-
matic light (540 6 10 nm) from a 250-W tungsten-halogen
lamp. Fluorescent and scattered light was collected by using an
image-intensified charge-coupled device camera (Dalsa, Wa-
terloo, Ontario). The data in Fig. 3C were gathered at a
3.75-ms sampling interval, acquiring from 96 3 96 sites
simultaneously over a 35 3 35 mm2 area. For Fig. 2, all data
were gathered at a 2-ms sampling rate, acquiring from 128 3
128 sites simultaneously over a 30 3 30 mm2 area.
The optical mapping data sets were processed through several
image-processing algorithms. First, a moving three-point median
was applied to the time series at each pixel, to remove spikelike
artifacts. Each pixel’s time series was then renormalized to a
scale of (0, 127). Then a nine-point weighted moving average
filter was applied to each pixel’s time series. Pixels that did not
meet a criterion of having at least two episodes with .15
consecutive frames above the average value at that pixel were not
analyzed. Finally, a nine-point spatial moving average filter was
applied.
Computer Simulations. Simulations were carried out in a three-
dimensional tissue model with the cable equation:
›V
›t
5 2IionyCm 1 „zD˜„V ,
where V is the transmembrane voltage, Cm 5 1 mFycm2 is the
capacitance, and D˜ is the diffusion tensor (18). The total ionic
current density Iion is taken from the phase I Luo-Rudy model
(19). The cable equation was integrated by an operator splitting
method and an adaptive time step method, with time step varying
from 0.02 ms to 0.2 ms (11). The tissue size was 4.8 3 4.8 3 0.9
cm, and the space step was 0.015 cm. Conduction anisotropy was
included in the model, with the fast axis rotating by 17°ymm, or
150° in all. To alter APD restitution curves, we modified
parameters and currents from the original model, as follows. In
all simulations, G# Na 5 16 mSycm2 and G# K 5 0.423 mSycm2. For
Fig. 4Ab, G# si 5 0.06; for Fig. 4Ac, G# si 5 0.045. In Fig. 4Bb, G# si 5
0.085; in Fig. 4Bc G# si 5 0.02. In both Fig. 4B b and c, Ca21
kinetics were sped up by replacing td and tf by 0.1*td and 0.1*tf
(following ref. 20). APD is defined as the duration during which
V . 272 ms, and DI as the duration during which V , 272 mV.
APD restitution was measured in a one-dimensional cable paced
at one end. We paced the cable at a fixed rate for 20 beats and
Fig. 1. (A) Effects of bretylium on APDR (a) and its slope (b), measured by the standard S1-S2 method. The effects on APDR slope in all six hearts is shown in
c (thin lines are control, thick lines are bretylium). (B) The effects of increasing bretylium dose on APDR during VF. (C) Transmembrane potential recording during
the bretylium-induced transition from VF to VT.
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Fig. 2. Effect of bretylium on spiral wave activity. Optical snapshots of voltage before and after the administration of 10 mM bretylium. Voltage is shown here
color-coded, from red (highest voltage) to blue (lowest). (A) Under control (drug-free) conditions, VF was characterized by multiple irregular wave fronts. These
give rise to the irregular segment of the transmembrane potential recording in Fig. 1C. (B) After bretylium administration, a pair of counter-rotating spiral waves
remains in the tissue and gives rise to the periodic transmembrane potential activity in Fig. 1C. The mapped region shown contains the lower of the two
counter-rotating spirals. Shown here are 10 snapshots, taken at evenly spaced 20-ms intervals. Note that two complete successive rotations of a stable spiral wave
can be seen. [These were two successive rotations of a nearly identical sequence of about 15 rotations that could be observed (data not shown).] (C) Twenty
successive 10-ms isochrones from the two rotations of the spiral wave shown in B. (Left) First rotation. (Right) Second rotation. Movies of the VF and VT episodes
are published as supplemental data on the PNAS web site, www.pnas.org.











measured DI and APD at the last two beats. The APDR curve
was obtained by sequentially increasing the pacing rate every 20
beats. All simulations were done on the massively parallel
supercomputers at the San Diego Supercomputing Center and
the Maui High Performance Computing Center. In the three-
dimensional blocks shown in Fig. 4, 1 sec of simulated time took
about 15 h on 31 processors.
Results
Bretylium. To test the restitution hypothesis experimentally, we
studied the drug bretylium, the only approved antiarrhythmic
drug that results in chemical defibrillation (21, 22). We found
that bretylium dramatically prevented VF in isolated arterially
perfused swine right ventricle (Fig. 1). When APD restitution
was measured (in the absence of VF), by introducing a prema-
ture stimulus during pacing, bretylium prolonged APD and also
flattened APDR slope (Fig. 1 A). In six pigs, the maximum
APDR slope (obtained from the best fit to a single exponential)
averaged 3.5 6 2.6 at baseline and 0.7 6 0.5 during bretylium
infusion (10–20 mgyml dose) (P , 0.01). The range of DIs for
which the APDR slope .1, an important determinant of the
tendency to fibrillation (9, 11), decreased from 22.3 6 6 ms to
zero in five of the preparations and to 5 ms in the remaining heart
(P , 0.01).
During VF, increasing doses of bretylium were associated with
a progressive decrease in the number of wave fronts, until only
a single wave front (or pair) remained, at which point VF
converted to stable monomorphic VT (Fig. 2). Transmembrane
Fig. 3. Bretylium 1 cromakalim. In these experiments, cromakalim was added to prevent APD prolongation by bretylium. (A) Compared with control (E and
thin lines), bretylium 1 cromakalim (F and thick lines) flattened APDR measured by the dynamic pacing method (a and b) and APDR during VF (c). (d)
Superimposed APDR slopes before (thin lines) and after bretylium 1 cromakalim (thick lines) in all five preparations. (B) Transmembrane potential recording
during the transition from VF to VT. (C) Gray-scale maps of voltage during VF (Left) and after bretylium 1 cromakalim (Right). Arrow shows fiber direction.
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voltage recordings showed a clear transition from irregular and
aperiodic activity in VF to periodic activity in VT (Fig. 1C).
We also constructed APD restitution curves during VF, from
transmembrane potential recordings at various bretylium doses
(Fig. 1B). APDR is complex during VF and is not defined by a
single curve, because of memory, wave curvature, and other
effects. Nevertheless, bretylium caused a clear decrease in the
steepness of APDR, particularly at short DIs, similar to its
effects on APDR slope during pacing in the absence of VF.
Most importantly, the voltage-sensitive dye maps of tissue
electrical activity showed clear decreases in the number and
complexity of wave fronts, as the dose of bretylium was increased
(Fig. 2). The reduction in wave fronts eventually resulted in a
conversion of VF to VT. Of six experiments, four showed a
transition from VF to VT, whereas the other two had their VF
terminated and converted to quiescent, excitable tissue (i.e.,
chemical defibrillation) (11). These findings support the resti-
tution hypothesis, which predicts that by flattening APDR,
bretylium should inhibit wave break, allowing fewer and fewer
re-entrant waves to survive.
Bretylium, in all cases, also prevented the reinduction of VT
or VF by the pacing protocol. After washout of bretylium, VF
was once again inducible by this protocol.
Bretylium Plus Cromakalim. One shortcoming of this experiment is
that, in addition to flattening APD restitution slope, bretylium
significantly increased APD, both during pacing (from 254 6 26
to 285 6 17 ms, P , 0.01) and in VF (from 67 6 18 to 89 6 30
ms, P , 0.01). Increased APD by itself can influence the
persistence of fibrillation, through its effects on wavelength (the
product of APD and CV) (23). Indeed, this is the basis for
so-called class III drug action. Therefore, it was possible that
bretylium’s effects on VF were primarily mediated through APD
prolongation (that is, its class III, K1-channel blocking action)
rather than by flattening the slope of APDR. (Bretylium gen-
erally is classified as a class III drug, that is, one that prolongs
APD; ref. 24.) To rule out this possibility, we used bretylium in
combination with a drug that prevented its APD-prolonging
effect, the ATP-sensitive K1-channel agonist cromakalim. In the
absence of bretylium, cromakalim decreased APD during VF
from 61 6 13 to 24 6 2 ms (P , 0.01). It did not decrease the
number of wave fronts or convert VF to VT (n 5 2). APD
restitution curves during both pacing and VF were shifted
downward, but otherwise they remained similar to control (data
not shown), and the maximum APDR slope was not significantly
affected (2.6 vs. 2.3, P 5 0.68).
We then tested the combination of bretylium with cromakalim
(Fig. 3). First, APD restitution was assessed in the absence of VF
by the dynamic pacing method (pacing at progressively faster
rates until 1:1 capture fails), recently shown to be superior to the
standard S1-S2 method for estimating the restitution that is
relevant to VF (25). In all five preparations, the maximum
APDR slope was greater than 1 (averaging 1.9 6 0.2), but
decreased to much less than 1 during cromakalim 1 bretylium
infusion (averaging 0.2 6 0.3) (P , 0.01) (Fig. 3 Aa). The range
of DIs for which APDR slope .1 also decreased, from 26 6 3.7
ms to zero in all five hearts (Fig. 3 Ab).
During VF, APD restitution is not a single-valued function;
nevertheless, the APDR steepness decreased markedly after
bretylium 1 cromakalim, as estimated by single exponential fits
(from 6.1 6 5.0 to 0.01 6 0.1, P , 0.01) (Fig. 3 A c and d). In
addition, the mean APD after bretylium 1 cromakalim was
shorter than under control conditions in all five preparations,
both during pacing (201 6 0.2 vs. 40 6 0.1 ms at the shortest DI)
and during VF (mean APD 72 6 12 vs. 21 6 1.4 ms). Thus, any
antifibrillatory effects of this drug combination cannot be at-
tributed to an increase in wavelength from APD prolongation
(i.e., class III action). Nor is it likely to have increased wavelength
by increasing CV, because a .3-fold increase in CV would be
required for the wavelength to increase, given the .3-fold
decrease in APD produced by the drug combination during VF.
Such an increase in CV was not observed (data not shown).
Voltage-sensitive dye maps of tissue electrical activity under
bretylium 1 cromakalim showed dramatic effects on wave fronts
during VF, similar to the effects of bretylium alone (Fig. 3C).
Under predrug control conditions, multiple wandering wavelets
were present, and transmembrane potential recordings showed
irregular action potentials of varying amplitude and duration
typical of VF. During bretylium 1 cromakalim infusion, how-
ever, the multiple wave fronts coalesced into a single spiral wave
Fig. 4. Computer simulation of effects of APD restitution on scroll wave
stability. (Aa) APDR curves (APD vs. DI) for the Luo-Rudy I ventricular action
potential model for two different values of G# si (the maximal value of the slow
inward Ca21 current). Prolonging APD by increasing G# si increased the slope of
the APDR curve. The dashed lines in Aa and Ba have slope 5 1. (A b and c)
Snapshots of voltage [coded from red, denoting depolarized tissue (highest
voltage) to blue for resting tissue (lowest voltage)], 1 sec after initiation of a
single scroll wave in a three-dimensional slab of cardiac tissue. The initial scroll
wave has spontaneously broken up into a fibrillation-like state for both
conditions. (Ad) Transmembrane potential from one cell in simulation Ab. (Ba)
Flattened APDR curves after modification of the Luo-Rudy action potential
model (see Methods), for two different mean values of APD. (B b and c)
Snapshots of voltage 2 sec after initiation of a single scroll wave, correspond-
ing to the two restitution curves above. In each case, the scroll wave remained
intact and did not break up into a fibrillation-like state. (Bd) Corresponding
transmembrane potential from simulation Bb.











within the mapped area (Fig. 3C), with periodic activation, as
reflected also in the transmembrane potential recording (Fig.
3B). Thus, VF was converted to VT. Similar results were
obtained in the other four preparations, all of which converted
from VF to VT during bretylium 1 cromakalim infusion.
Bretylium plus cromakalim also prevented the reinduction of
VTyVF by the pacing protocol. After washout of the drugs, VF
was once again inducible by the pacing protocol.
Computer Simulation. As a final demonstration that it is restitution
slope that is the critical antifibrillatory parameter, we con-
structed computer simulations of the breakdown of scroll waves
(the three-dimensional analogue of spiral waves) into VF-like
states. We simulated three-dimensional blocks of tissue, using a
modified Luo-Rudy I (19) ventricular cell model. Under control
conditions, APDR slope is .1 over a significant range of DIs
(Fig. 4Aa, curve c). As predicted by the restitution hypothesis, a
scroll wave induced by cross-field stimulation (26) spontaneously
breaks up into a fibrillation-like state (Fig. 4Ac), whose temporal
behavior is irregular (Fig. 4Ad). Prolonging APD to simulate a
class III antiarrhythmic action (Fig. 4Aa, curve b) further
steepens APDR and does not prevent spiral wave breakup (Fig.
4Ab). In contrast, if APDR slope is f lattened to ,1 (Fig. 4Ba,
curves b and c), spiral wave breakup is prevented (Fig. 4B b and
c), and the resulting temporal behavior is regular (Fig. 4Bd).
Note that this antifibrillatory effect is independent of mean
APD, occurring whether APD is short or long (Fig. 4B).
Discussion
These results strongly imply that bretylium’s primary antifibril-
latory effect comes through flattening APD restitution, and
hence preventing wave break, as predicted by the restitution
hypothesis. [Although bretylium has other actions, e.g., promi-
nent autonomic effects (27), these are unlikely to have been
important in the isolated, denervated preparations used in this
study. Also, previous studies have concluded that bretylium’s
antifibrillatory action is unrelated to its autonomic actions (28,
29).] Thus, our results indicate that for normal swine right
ventricular tissue, dynamic heterogeneity caused by cardiac
restitution properties is more important than fixed electrophys-
iological and anatomical heterogeneities in the genesis and
maintenance of VF. Whether this is true in the thicker left
ventricle, with its greater degree of fixed anatomic and regional
electrophysiological heterogeneity, or in diseased hearts in which
fixed heterogeneity is further enhanced, is not clear. In partic-
ular, the role of thickness and fiber twist (18) require further
study. But Gilmour’s group (13) recently reported that the drugs
verapamil (at high concentrations) and diacetyl monoxime,
which flatten APD restitution by different mechanisms than
does bretylium, also prevented VF in the normal canine left
ventricle. And, as noted earlier, bretylium has been shown to
abolish VF in both normal and diseased hearts (27–30).
Based on these results, drugs that flatten APD restitution in
the ventricle appear to hold great promise as antifibrillatory
agents and may prove useful in preventing sudden cardiac death.
Hopefully, this can reverse the trend of recent clinical antiar-
rhythmic drug trials, which have been disappointing at best and
disastrous at worst (31–33). Bretylium, although not itself clin-
ically useful for ambulatory patients because of its profound
autonomic side effects, may serve as a prototype for developing
novel antifibrillatory agents. The present study, by elucidating its
mechanism of action, provides a template for the screening of
these drugs.
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